Type 1 diabetes mellitus results from the autoimmune destruction of the insulin producing
pancreatic β-cells. The autoimmune response begins months or even years before the
presentation of hyperglycemic symptoms. Previous studies with other autoimmune diseases or
acute inflammatory diseases testing the effect of the infusion of mesenchymal stem cells
showed promising results in regulating immune system and promoting some degree of disease
control. The aim of our study is to determine the safety and efficacy of intravenous
infusions of mesenchymal stem cells in newly diagnosed type 1 diabetic patients.